Evolus (id:6547 EOLS)
13.04 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/21/2024 6:51:20 PM)
Exchange closed, opens in 14 hours 38 minutes
2.76 USD (2.76%)
8.94 USD (8.94%)
-22.93 USD (-22.93%)
3.57 USD (3.57%)
37.12 USD (37.12%)
-5.92 USD (-5.92%)
15.91 USD (15.91%)
About Evolus
Market Capitalization 799.75M
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
| Headquarters (address) |
520 Newport Center Drive Newport Beach 92660 CA United States |
| Phone | 949 284 4555 |
| Website | https://www.evolus.com |
| Employees | 273 |
| Sector | Healthcare |
| Industry | Drug Manufacturers Specialty & Generic |
| Ticker | EOLS |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 9.29 - 17.82 |
| Market Capitalization | 799.75M |
| P/E trailing | -11.69 |
| P/E forward | 63.15 |
| Price/Sale | 3.22 |
| Price/Book | 135.81 |
| Beta | 1.32 |
| EPS | -0.910 |
| EPS United States (ID:6, base:3395) | 24.30 |